



OFFICE of the DEPUTY PRIME MINISTER  
MINISTRY for HEALTH  
15, PALAZZO CASTELLANIA, MERCHANTS STREET, VALLETTA, MALTA

**DH CIRCULAR 73/2017**  
DH 1146/2017

13<sup>th</sup> September 2017

**Attention All:** Consultants  
Medical Officers  
Pharmacists  
Pharmacy Technicians  
Nurses

**Re: Bevacizumab 100mg/4mL Vials**

In line with Government's commitment to increase the availability of oncology medicines on the Government Formulary List (GFL), **with immediate effect** the clinical indications for the use of Bevacizumab 100mg/4mL vials are being extended to include recurrent or metastatic cervical cancer and ovarian cancer.

**Bevacizumab 100mg/4mL vials can now be prescribed by Consultant Oncologist according to protocol 225 which has been updated to include the new indications as per Annex 1.**

For your attention please.

Dr Denis Vella Baldacchino  
Chief Medical Officer

## **Bevacizumab 100mg/4mL Vials**

### **Part A**

**Prescriber Criteria:** Consultant Ophthalmologist

**In-patient use:**

Exudative age-related macular degeneration and other ocular vascular proliferations e.g. Diabetic Rubeosis (off-license indication).

### **Part B**

**Prescriber Criteria:** Consultant Oncologist

**In-patient use:**

- In combination with other drugs for recurrent or metastatic cervical cancer
- In combination with other drugs for the treatment of first-recurrence of platinum-sensitive epithelial ovarian cancer
- In recurrent or metastatic epithelial ovarian cancer in combination with other drugs in patients who have received no more than two prior chemotherapy regimen.